Josephine Hellschlienger News Today

Total revenue of $7 million, compared to $101 million in Q3 2022Total cumulative partnered program starts of 110, up 20% from Q3 2022Net loss of $0.10 per share on a basic and diluted basis, compared to net earnings of $0.09 and $0.08 per share on a basic and diluted basis, respectively, in Q3 2022VANCOUVER, British...

Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degraderWILMINGTON, Del. & VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and A...

VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) will announce its third quarter 2023 financial results on Thursday, November 2, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.A live audio webcast of the earnings conference may...

VANCOUVER, British Columbia —

PTAB rejects request by Berkeley Lights to reconsider its decision denying Berkeley's argument that AbCellera’s U.S. patent is invalidVANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) announced that the United States Patent and Trademark Office’s (USPTO) Patent Trial and Appeal Board (PTA...

VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) will announce its second quarter 2023 financial results on Thursday, August 3, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.A live audio webcast of the earnings conference may b...

Total revenue of $12 million, compared to $317 million in Q1 2022Total cumulative partnered program starts of 101, up 20% from Q1 2022Net loss of $0.14 per share on a basic and diluted basis, compared to net earnings of $0.59 (basic) and $0.54 (diluted) per share in Q1 2022VANCOUVER, British Columbia--(BUSINESS WIRE...

VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, April 25, 2023, at 6:30 a.m. Pacific Time (9:30 a.m. Eastern Time).A live audio webcast of t...

VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) will announce its first quarter 2023 financial results on Thursday, May 4, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.A live audio webcast of the earnings conference may be ac...

VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) today announced two upcoming poster presentations on its T-cell engager platform at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held at the Orange County Convention Center in Orlando, Florida, from April...